01 / Contract Profile
75F40119C10101 Federal Contract Award
Agency code 7524
BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31.
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75F40119C10101 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations-$17.7K
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2019 | $1.92M | 1 | — |
| FY 2021 | $0 | 1 | −100.0% |
| FY 2022 | $0 | 3 | — |
| FY 2023 | $0 | 1 | — |
| FY 2025 | $0 | 2 | — |
| FY 2026 | -$17.7K | 1 | — |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | FOOD AND DRUG ADMINISTRATION | FDA OFFICE OF ACQ GRANT SVCS |
05 / Contractor
Who holds this federal contract?
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
UEI QHF5ZZ114M72 · CAGE 3FHD3
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541715 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) | $1.90M | 9 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AN22 | HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH | $1.90M | 9 | 100.0% |
08 / Place of Performance
Where is the work recorded?
NEW YORK, NEW YORK, NEW YORK, UNITED STATES
ZIP 100323725
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Jul 26, 2026 | P00008 | -$17.7K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Sep 29, 2025 | P00007 | $144.3K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Sep 2, 2025 | P00006 | -$144.3K | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Mar 15, 2023 | P00005 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Oct 13, 2022 | P00004 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Jul 16, 2022 | P00003 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Mar 30, 2022 | P00002 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Nov 10, 2021 | P00001 | $0 | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
| Sep 21, 2019 | Base action | $1.92M | FDA OFFICE OF ACQ GRANT SVCSOffice code 75F401 | 541715 | AN22 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.